Elite Pharmaceuticals Inc (ELTP) stock
Close on Oct 19, 2026Market cap $283.02MP/E 5.0Yield –
Earnings
Elite Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Elite Pharmaceuticals's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q3 FY2027ended Dec 31, 2026 | Feb 16, 2027Expected | – | – | – | – |
| Q2 FY2027ended Sep 30, 2026 | Nov 12, 2026after the close | $40.10M | +10.5% | – | Release |
| Q1 FY2027ended Jun 30, 2026 | Aug 13, 2026during market hours | $32.40M | -19.4% | – | Release |
| Q4 FY2026ended Mar 31, 2026 | Jun 29, 2026during market hours | $148.90M | – | – | Release |
| Q3 FY2026ended Dec 31, 2025 | Feb 17, 2026during market hours | $31.60M | +119.4% | – | Release |
| Q2 FY2026ended Sep 30, 2025 | Nov 14, 2025during market hours | $36.30M | +92.1% | – | Release |
| Q1 FY2026ended Jun 30, 2025 | Aug 14, 2025during market hours | $40.20M | – | – | Release |
| Q4 FY2025ended Mar 31, 2025 | Jun 30, 2025during market hours | – | – | – | Release |
| Q3 FY2025ended Dec 31, 2024 | Feb 13, 2025during market hours | $14.40M | – | – | Release |
| Q2 FY2025ended Sep 30, 2024 | Nov 14, 2024during market hours | $18.90M | – | – | Release |
| Q1 FY2025ended Jun 30, 2024 | Aug 14, 2024during market hours | – | – | – | Release |
| Q3 FY2024ended Dec 31, 2023 | Feb 14, 2024during market hours | – | – | – | Release |
| Q2 FY2024ended Sep 30, 2023 | Nov 14, 2023during market hours | – | – | – | Release |
| Q1 FY2024ended Jun 30, 2023 | Aug 14, 2023during market hours | – | – | – | Release |
| Q4 FY2023ended Mar 31, 2023 | Jun 29, 2023during market hours | – | – | – | Release |
| Q3 FY2023ended Dec 31, 2022 | Feb 14, 2023during market hours | – | – | – | Release |
| Q2 FY2023ended Sep 30, 2022 | Nov 15, 2022before the open | – | – | – | Release |
| Q1 FY2023ended Jun 30, 2022 | Aug 15, 2022during market hours | – | – | – | Release |
| Q4 FY2022ended Mar 31, 2022 | Jun 29, 2022during market hours | – | – | – | Release |
| Q3 FY2022ended Dec 31, 2021 | Feb 15, 2022during market hours | – | – | – | Release |
| Q2 FY2022ended Sep 30, 2021 | Nov 15, 2021during market hours | – | – | – | Release |
| Q1 FY2022ended Jun 30, 2021 | Aug 16, 2021during market hours | – | – | – | Filing |
| Q4 FY2021ended Mar 31, 2021 | Jun 14, 2021during market hours | – | – | – | Filing |
| Q3 FY2021ended Dec 31, 2020 | Feb 16, 2021during market hours | – | – | – | Filing |
| Q2 FY2021ended Sep 30, 2020 | Nov 16, 2020during market hours | – | – | – | Filing |
| Q1 FY2021ended Jun 30, 2020 | Aug 17, 2020before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Elite Pharmaceuticals has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Elite Pharmaceuticals puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Elite Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- Update
- Update
- Update
- Results
- Update
- Update
- Update
- Update
- Results
- Update
- Results
See a number that looks wrong?